NCT06909890 A Study of Chios Mastic Water in Dyspepsia
| NCT ID | NCT06909890 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Harokopio University |
| Condition | Dyspepsia |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2025-07-10 |
| Primary Completion | 2026-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2025-07-10 with a primary completion date of 2026-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Chios mastic is a natural product with strong antimicrobial, anti-inflammatory and antioxidant properties, and well-established benefits for dyspeptic disorders. The aim of the present study is to investigate the effectiveness of a natural aqueous extract of Chios mastic (mastic water), a by-product of Chios mastic processing, in the management of dyspepsia. This will be a 3-month randomized double-blind controlled clinical trial in adults with dyspepsia. Participants will be blindly randomized to an intervention group, which will receive 600 mL/d of a carbonated beverage enriched with Chios mastic water (0.2%), or a control group, which will receive 600 mL/d of an identical placebo beverage with no active ingredients. Participants will be evaluated in terms of anthropometric indices, lifestyle habits, severity of dyspepsia-related gastrointestinal symptoms, quality of life, as well as biochemical markers, both pre- and post-intervention.
Eligibility Criteria
Inclusion Criteria: * Age 30-60 years old. * Body mass index of 20-35 kg/m2. * Presence of dyspepsia. Exclusion Criteria: * Presence of chronic diseases (e.g. diabetes mellitus, cancer, cardiovascular, hepatic, renal, respiratory, chronic inflammatory and psychiatric diseases). * Presence of other chronic gastrointestinal diseases (e.g. gastroesophageal reflux, inflammatory bowel disease and celiac disease). * Use of immunosuppressants, anti-inflammatories, antibiotics and corticosteroids. * Use of dietary supplements or other products with Chios mastic. * Excessive alcohol consumption (\>210 g and \>140 g of ethanol per week for men and women, respectively). * Currently on a weight-loss diet or recent (within 6 months) significant change in lifestyle habits. * Pregnancy or breast feeding (for women)
Contact & Investigator
Giannis Arnaoutis, PhD
PRINCIPAL INVESTIGATOR
Department of Nutrition and Dietetics, School of Health Sciences and Education, Harokopio University of Athens
Frequently Asked Questions
Who can join the NCT06909890 clinical trial?
This trial is open to participants of all sexes, aged 30 Years or older, up to 60 Years, studying Dyspepsia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06909890 currently recruiting?
Yes, NCT06909890 is actively recruiting participants. Contact the research team at garn@hua.gr for enrollment information.
Where is the NCT06909890 trial being conducted?
This trial is being conducted at Kallithea, Greece.
Who is sponsoring the NCT06909890 clinical trial?
NCT06909890 is sponsored by Harokopio University. The principal investigator is Giannis Arnaoutis, PhD at Department of Nutrition and Dietetics, School of Health Sciences and Education, Harokopio University of Athens. The trial plans to enroll 60 participants.